Skip to main content

Table 2 Inclusion criteria of patients enrolled in CVOTs referred to in the text

From: Updates on cardiovascular outcome trials in diabetes

  Age Diabetes type HbA1c levels Cardiovascular status Prior anti hyperglycaemic treatment BMI (Kg/m2)
SAVOR-TIMI53 ≥ 40 T2DM ≥ 6.5% CVD or high CV risk AHA 31.1
EXAMINE ≥ 18 T2DM (6.5, 11.0%) ACS (15, 90) days before AHA 28.7
TECOS ≥ 50 T2DM (6.5, 8.0%) pre-existing CVD AHA 30.2
ELIXA ≥ 30 T2DM ≥ 7.0% ACS min. 180 days before AHA 30.2
EMPA-REG OUTCOME ≥ 18 T2DM (7.0, 10.0%) Pre-existing CVD Drug naive or AHA ≤ 45
LEADER ≥ 50 T2DM ≥ 7.0% Pre-existing CVD/cerebrovascular disease/vascular disease/renal or heart failure at ≥ 50 or CV risk at ≥ 60 Drug naive or AHA 32.5
SUSTAIN6 ≥ 50 T2DM ≥ 7.0% Pre-existing CVD at ≥ 50 OR pre-CVD at ≥ 60 Drug naive or AHA 31.1
EXSCEL ≥ 18 T2DM 6.5–10.0% 73.1% with previous CVD Specific AHA
CAROLINA ≥ 40 ≤ 85 T2DM (6.5, 7.5–8.5%) CVD or specified diabetes end-organ damage or age ≥ 70 years or ≥ 2 specified CV risk factors ≤ 45
REWIND ≥ 50 T2DM ≤ 9.5% Pre-existing vascular disease or ≥ CV risk factors AHA
ITCA650 ≥ 40 T2DM ≥ 6.5% Pre-existing coronary, cerebrovascular or peripheral artery disease
DECLARE-TIMI ≥ 40 T2DM High risk CV events
CARMELINA ≥ 18 T2DM (6.5, 10.0%) High risk CV events Drug naive or specific AHA ≤ 45
DEVOTE ≥ 50 T2DM ≤ 7.0% CVD or renal disease or ≥ 60 CV risk Specific AHA
MK-3102 ≥ 40 T2DM (6.5, 10.0%) Pre-existing vascular disease
VERTIS ≥ 40 T2DM (7.0, 10.5%) Pre-existing vascular disease Drug naive or AHA ≥ 18
CANVAS program ≥ 40 T2DM (7.0, 10.5%) Pre-existing CVD or high CV risk Drug naive or AHA
Albiglutide trial ≥ 40 T2DM > 7.0% CVD
ACE ≥ 65 Prediabetes 5.9% CV event within the last 3 month Drug naive 25